6/26/2019  5:35:59 PM Chg. - Volume Bid9:02:26 AM Ask9:02:26 AM Market Capitalization Dividend Y. P/E Ratio
23.200EUR - 0
Turnover: 0.000
23.100Bid Size: 499 23.300Ask Size: 50 906.2 mill.EUR 0.00% 5.00

Business description

Biotest is a provider of plasma proteins and biotherapeutic drugs. With a value added chain that extends from pre-clinical and clinical development to worldwide sales, Biotest has specialised primarily in the areas of clinical immunology, haematology and intensive medicine. Biotest develops and markets immunoglobulins, coagulation factors and albumins based on human blood plasma. These are used for diseases of the immune and haematopoietic systems. In addition Biotest develops monoclonal antibodies in the indications of rheumatoid arthritis and cancer of plasma cells, which are produced by recombinant technologies.
 

Management board & Supervisory board

CEO
Dr. Bernhard Ehmer (bis 30.04.2019)
Management board
Dr. Michael Ramroth (CEO ab 1.05.2019), Dr. Georg Floß
Supervisory board
Rolf Hoffmann, Tan Yang, Christine Kreidl, Dr. Cathrin Schleussner, Jürgen Heilmann, Kerstin Birkhahn
 

Company data

Name: Biotest AG
Address: Landsteinerstraße 5,D-63303 Dreieich
Phone: +49-6103-801-0
Fax: +49-6103-801-150
E-mail: mail@biotest.de
Internet: www.biotest.de
Industry: Healthcare
Sector: Medical Products
Sub sector: Advanced Medical Devices
End of financial year: 12/31
Free Float: 52.56%
IPO date: 10/14/1987

Investor relations

Name: Dr. Monika Buttkereit
IR phone: +49-6103-801-4406
IR-Fax: +49-6103-801-347
IR e-mail: investor_relations@biotest.de

Company calendar

CW 33 | 8/14/2019 Interim Report 2nd Quarter/6 Months
CW 46 | 11/14/2019 Interim Report 3rd Quarter/9 Months
 

Main Shareholders

Tiancheng (Germany) Pharmaceutical Holdings AG
 
89.88%
Freefloat
 
5.12%
J O Hambro Capital Management
 
5.00%